Fulgent Genetics (NASDAQ:FLGT) Insider Sells $16,632.00 in Stock

Fulgent Genetics, Inc. (NASDAQ:FLGT) insider Hanlin Gao sold 945 shares of Fulgent Genetics stock in a transaction dated Wednesday, May 27th. The shares were sold at an average price of $17.60, for a total value of $16,632.00. Following the transaction, the insider directly owned 992,062 shares in the company, valued at approximately $17,460,291.20. This trade represents a 0.10% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Fulgent Genetics Stock Performance

Shares of NASDAQ FLGT traded up $0.34 during mid-day trading on Thursday, reaching $18.24. The company had a trading volume of 478,192 shares, compared to its average volume of 502,915. The company has a market capitalization of $518.03 million, a price-to-earnings ratio of -7.63 and a beta of 0.88. The stock has a fifty day moving average of $16.04 and a two-hundred day moving average of $21.94. Fulgent Genetics, Inc. has a 12-month low of $13.46 and a 12-month high of $31.04.

Fulgent Genetics (NASDAQ:FLGT) last announced its quarterly earnings data on Friday, February 27th. The company reported $0.16 EPS for the quarter, beating analysts’ consensus estimates of $0.02 by $0.14. Fulgent Genetics had a negative net margin of 23.04% and a negative return on equity of 3.24%. The firm had revenue of $83.34 million for the quarter, compared to the consensus estimate of $85.38 million. Fulgent Genetics has set its FY 2026 guidance at -1.450–1.450 EPS. Sell-side analysts forecast that Fulgent Genetics, Inc. will post -2.81 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms recently issued reports on FLGT. Zacks Research cut Fulgent Genetics from a “strong-buy” rating to a “hold” rating in a research report on Monday, February 9th. Piper Sandler reissued a “neutral” rating and issued a $15.00 price target (down from $30.00) on shares of Fulgent Genetics in a research note on Tuesday, May 5th. Finally, Wall Street Zen downgraded Fulgent Genetics from a “sell” rating to a “strong sell” rating in a report on Saturday, May 9th. Two analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $27.00.

Institutional Investors Weigh In On Fulgent Genetics

A number of institutional investors have recently added to or reduced their stakes in FLGT. Allianz Asset Management GmbH increased its stake in Fulgent Genetics by 119.6% during the third quarter. Allianz Asset Management GmbH now owns 90,869 shares of the company’s stock valued at $2,054,000 after acquiring an additional 49,485 shares during the period. JPMorgan Chase & Co. grew its holdings in shares of Fulgent Genetics by 767.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 299,014 shares of the company’s stock worth $6,758,000 after purchasing an additional 264,524 shares in the last quarter. Hennion & Walsh Asset Management Inc. bought a new stake in shares of Fulgent Genetics during the fourth quarter valued at approximately $1,739,000. Northwestern Mutual Wealth Management Co. raised its stake in shares of Fulgent Genetics by 2,984,354.9% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 1,522,072 shares of the company’s stock valued at $39,985,000 after purchasing an additional 1,522,021 shares in the last quarter. Finally, UBS Group AG raised its stake in shares of Fulgent Genetics by 288.8% in the fourth quarter. UBS Group AG now owns 83,559 shares of the company’s stock valued at $2,195,000 after purchasing an additional 62,070 shares in the last quarter. 48.06% of the stock is owned by institutional investors and hedge funds.

About Fulgent Genetics

Fulgent Genetics, Inc (NASDAQ: FLGT) is a California-based company specializing in high-complexity genetic testing and diagnostic services. Operating from its headquarters in Temple City, Fulgent leverages next-generation sequencing (NGS) technologies and advanced bioinformatics to deliver a broad range of clinical and research assays. The company’s infrastructure includes CAP- and CLIA-certified laboratories, enabling it to process large volumes of samples with rapid turnaround times.

Fulgent’s product portfolio encompasses hereditary cancer panels, rare disease and neuromuscular disorder testing, pharmacogenomic screenings, non-invasive prenatal tests, and infectious disease assays including COVID-19 diagnostics.